Abbott and Enanta Present Positive Initial Results from Phase 2 Study of ABT-450/r for Treatment of Hepatitis C
5 November 2010
4 views
No Comment
Abbott Park, Illinois, and Watertown, Massachusetts — Abbott (NYSE: ABT) and Enanta Pharmaceuticals today announced positive results from a Phase 2 study of ABT-450/r, an investigational, oral protease inhibitor being developed for the treatment of hepatitis C (HCV) infection. Initial 3-day and 4-week results suggest that ABT-450/r (ABT-450 with 100mg of ritonavir to support once-daily dosing) demonstrates potent antiviral activity in treatment-naïve adults. Results show that more than 90 percent of patients (21 of 23) on study drug achieved HCV-RNA levels
Related posts:
- Abbott and Enanta Announce Advancement of Hepatitis C Collaboration
- Abbott Announces Positive Results from Phase 2 Study of Low Dose Atrasentan for Treatment of Diabetic Kidney Disease
- Reata and Abbott Announce Positive Phase 2b Study Results for Bardoxolone Methyl
- Week 24 interim results from phase 2b PILLAR study to be presented as late-breaker at AASLD
- U.S. Food and Drug Administration Approves BARACLUDE (entecavir) as a Treatment for Chronic Hepatitis B Patients with Evidence of Decompensated Liver Disease
Have your say!